| Recruiting | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors NCT06581419 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignan NCT06394713 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. NCT06297642 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Completed | A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer NCT06344351 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets NCT06165822 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Withdrawn | A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer NCT06165809 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Terminated | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies NCT05861947 | Aurigene Discovery Technologies Limited | Phase 1 |
| Completed | A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor NCT05997342 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy NCT05985278 | Peking University Cancer Hospital & Institute | EARLY_Phase 1 |
| Unknown | Clinical Trial Evaluating the Safety of the TQB2103 for Injection NCT05867563 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm NCT05048160 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Recruiting | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies NCT04503265 | AtlasMedx, Incorporated | Phase 1 / Phase 2 |
| Active Not Recruiting | Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advance NCT03203525 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Cordotomy in Reducing Pain in Patients With Advanced Cancer NCT04119037 | M.D. Anderson Cancer Center | N/A |
| Recruiting | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia NCT04067336 | Kura Oncology, Inc. | Phase 1 / Phase 2 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Financial Distress in Advanced Cancer Patients NCT04053517 | M.D. Anderson Cancer Center | — |
| Completed | Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and NCT03856060 | M.D. Anderson Cancer Center | N/A |
| Completed | Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings NCT04186884 | M.D. Anderson Cancer Center | — |
| Withdrawn | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Ca NCT03868423 | Sameek Roychowdhury | Phase 2 |
| Active Not Recruiting | Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer NCT03671226 | M.D. Anderson Cancer Center | N/A |
| Withdrawn | Rectal Administration of Opioids Using the Macy Catheter in Reducing Pain in Patients With Advanced Cancer NCT03592459 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy NCT03525873 | M.D. Anderson Cancer Center | Phase 3 |
| Active Not Recruiting | RCT of QPS vs General Information Sheet NCT03287492 | M.D. Anderson Cancer Center | N/A |
| Completed | Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxalipl NCT03122886 | Mayo Clinic | N/A |
| Active Not Recruiting | Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recu NCT03021486 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Terminated | First-in-Human Study of KO-947 in Non-Hematological Malignancies NCT03051035 | Kura Oncology, Inc. | Phase 1 |
| Terminated | Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer NCT03049397 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer NCT02940223 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor NCT03069469 | Deciphera Pharmaceuticals, LLC | Phase 1 / Phase 2 |
| Completed | Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients NCT02823652 | ECOG-ACRIN Cancer Research Group | N/A |
| Completed | Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by S NCT02583269 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Enhancing Connections Program in Improving Communication Between Patients With Incurable Cancer and Their Chil NCT02650583 | University of Washington | N/A |
| Active Not Recruiting | Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer NCT02491632 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations i NCT02286687 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab NCT01867294 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers NCT01624766 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer NCT01582191 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mu NCT01531361 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey NCT01549067 | Chinese Medical Doctor Association | — |
| Completed | Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer NCT00244972 | National Cancer Institute (NCI) | Phase 1 |
| Available | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors NCT06872489 | Second Life Therapeutics | — |